Last Updated : January 15, 2024
Details
FilesGeneric Name:
mepolizumab
Project Status:
Active
Therapeutic Area:
Eosinophilic Granulomatosis with Polyangiitis
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
SX0839-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Fee Schedule:
Pending
Indications:
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submission received | 19-Dec-23 |
---|
Files
Last Updated : January 15, 2024